pan-PPAR agonist lanifibranor has demonstrated efficacy in modulating both metabolic–immune markers [95] and fibrosis [96] in patients with metabolic dysfunction-associated steatohepatitis (MASH). The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.